Pharmaceutical products

Tender description

NHS National Pharmaceuticals Transition 2020_2 Offer reference number: CM/PHG/20/5618 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months) Potential periods of call-offs under the framework agreement Transition products: LSNE 1 December 2020 to 30 September 2021 (10 months) NWLN 1 December 2020 to 31 January 2022 (14 months) CESW 1 December 2020 to 30 June 2022 (19 months) Hospital only products: All Regions 1 December 2020 to 31 January 2022 (14 months) Products on the framework include (but are not limited to): Ambrisentan Deferiprone Fosaprepitant Micafungin Noradrenaline (RTU presentations only) Oseltamivir Oxycodone/Naloxone (combination) Prasugrel Solifenacin Temsirolimus Thalidomide Tipranavir Tolvaptan Co-Amoxiclav Valganciclovir Valaciclovir Piperacillin/Tazobactam Pdr for Inj Vial 4g/500mg NHS National Pharmaceuticals Transition 2020_2 Offer reference number: CM/PHG/20/5618 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement Transition products: LSNE 1 December 2020 to 30 September 2021 (10 months) NWLN 1 December 2020 to 31 January 2022 (14 months) CESW 1 December 2020 to 30 June 2022 (19 months) Hospital only products: All Regions 1 December 2020 to 31 January 2022 (14 months). NHS National Pharmaceuticals Transition 2020_2 Offer reference number: CM/PHG/20/5618 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement. Transition products: LSNE 1 December 2020 to 30 September 2021 (10 months) NWLN 1 December 2020 to 31 January 2022 (14 months) CESW 1 December 2020 to 30 June 2022 (19 months) Hospital only products: All Regions 1 December 2020 to 31 January 2022 (14 months). NHS National Pharmaceuticals Transition 2020_2 Offer reference number: CM/PHG/20/5618 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months). Potential periods of call-offs under the framework agreement Transition products: LSNE 1 December 2020 to 30 September 2021 (10 months) NWLN 1 December 2020 to 31 January 2022 (14 months) CESW 1 December 2020 to 30 June 2022 (19 months) Hospital only products: All Regions 1 December 2020 to 31 January 2022 (14 months). NHS National Pharmaceuticals Transition 2020_2 Offer reference number: CM/PHG/20/5618 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months) Potential periods of call-offs under the framework agreement Transition products: LSNE 1 December 2020 to 30 September 2021 (10 months) NWLN 1 December 2020 to 31 January 2022 (14 months) CESW 1 December 2020 to 30 June 2022 (19 months) Hospital only products: All Regions 1 December 2020 to 31 January 2022 (14 months).